Superficial vein thrombosis: a current approach to management

Abstract

SummarySuperficial vein thrombosis (SVT) was considered to be a benign and self-limiting condition. However, it is now appreciated that a significant proportion of those presenting with SVT will have concomitant deep vein thrombosis or pulmonary embolism, or are at significant risk of developing deep venous thromboembolism. Potential therapeutic options include topical preparations, compression therapy (stockings, bandages), medication such as non-steroidal anti-inflammatory drugs (NSAIDs) or anticoagulants (therapeutic or prophylactic doses) and surgery, ligation or stripping, of superficial veins. The treatment of choice is therapeutic/intermediate dose low molecular weight heparin or prophylactic dose fondaparinux administered for 4-6 weeks. The costeffectiveness of treatment is a concern and more targeted therapy is required.

Use of Rivaroxaban for Prophylaxis of Superficial Venous Thrombosis in Klippel-Trenaunay-Weber Syndrome

“…11 Finally, prophylactic dose anticoagulation has been shown to be effective in the treatment of SVT. 9 In conclusion, KTWS is a rare condition that can be complicated by a variety of thrombotic manifestations. Recurrent overt thrombotic events may be successfully treated with anticoagulation.…”

“…There is data to support the use of short term low dose anticoagulation in the treatment of acute superficial vein thrombosis (SVT). 9 Randomized controlled studies have demonstrated the efficacy and safety of systemic anticoagulation with therapeutic/intermediate doses of LMWH or prophylactic doses of fondaparinux administered for 4-6 weeks. 9 Fondaparinux 2.5 mg/day is currently the only anticoagulant with a license for the treatment of SVT.…”

“…9 Randomized controlled studies have demonstrated the efficacy and safety of systemic anticoagulation with therapeutic/intermediate doses of LMWH or prophylactic doses of fondaparinux administered for 4-6 weeks. 9 Fondaparinux 2.5 mg/day is currently the only anticoagulant with a license for the treatment of SVT. 23 With a large permanent venous malformation and previous recurrent thrombotic events within this vascular system, we elected to extend anticoagulation to indefinite duration.…”

Practical Approach to VTE Management in Hospitalized Patients

“…Significant number (25%) of patients with SVT shows gradual extension in the vein to manifest as DVT and PE. 127,128 When SVT of the lower limbs extends .5 cm in length, it should be treated for 45 days with prophylactic doses of FON or LMWH in combination with anti-inflammatory agents. 129 Provoked SVT typically occurs in upper extremities (cephalic and basilic veins), following the placement of IV lines (peripheral IV catheters or PICC).…”

Prevalence of the genetic mutations in patients with varicose veins

“…Ayrıca, variköz venlerde gelişen YVT ilerleyerek derin ven sistemine geçebileceğinden özellikle tromboze variköz venleri olan hastaların sıkı takibi gerekir. Safenofemoral kavşağa 3 cm'den daha yakın yüzeyel ven trombozlarında olası komplikasyonları önlemek için antikoagülan tedavi ve cerrahi ligasyon veya trombektomi uygulanmalıdır (15). FVL mutasyonu beyaz ırkta en yaygın rastlanan kalıtsal trombofili nedenidir.…”